Piramal Pharma Limited (PPLPHARMA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Piramal Pharma Limited, explained in plain English.

• ▪Piramal Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪PPLPHARMA closed at ₹235.80 on 30 October 2026.
• ▪Over the past year the shares are up 16.8%, trading between ₹132.30 and ₹239.54.
• ▪Reported fundamentals show return on equity of -2.58%, a net margin of -2.14%, debt to equity of 71.93.
• ▪Our transparent MaxGrade checklist scores it C (56/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 37.83% with a maximum drawdown of -33.88% and a beta of 1.08 against NIFTY 50.
• ▪Recent coverage: Acutaas Chemicals among 5 stocks hitting 52-week highs; rallied up to 18% in a month
• ▪Recent coverage: Piramal Pharma cuts exposure to Chinese raw materials to reduce supply risk

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Figures from the current session. Market open.